32nd World Seminar on Neurology and Spine Disorders
  • Follow

Accepted Abstracts

Quality Control of Mitochondria in Parkinsons Disease (PD) Using ATP and Bradford Assays

Al-Baraa Akram El-Sayed*
Department of Pharmaceutical Biotechnology, Portland laboratory in De Montfort University in Leicester, United Kingdom.

Citation: El-Sayed AlBA (2022) Quality Control of Mitochondria in Parkinsons Disease (PD) Using ATP and Bradford Assays. SciTech Central Neurology 2022.

Received: May 26, 2022         Accepted: May 30, 2022         Published: May 30, 2022

Abstract

Parkinsons disease is a heterogeneous, multifactorial and often complex disease characterized by motor impairment due to the presence of Lewy bodies and prominent degeneration of dopaminergic neurons in the substantia nigra. Although the specific pathogenesis involving PD remains under investigation, mitochondrial dysfunction has been widely accepted as one of the major pathogenic pathways underlying the development of PD. Based on the hypothesis that depiction of HtrA2 (serine protease gene, mitochondrial precursor) might contribute to an increase in mitochondrial stress and transcriptional up regulation of the nuclear stress response CHOP gene. The present study aimed to analyze through laboratory based research the role of HtrA2 and CHOP in the transmission of stress signaling and the consequent activation of mitochondrial quality control in Parkinson's disease using ATP and Bradford assays.
Keywords: Parkinson's disease, Lewy bodies, Mitochondrial dysfunction, Bradford assays